6th Diabetes Drug Discovery & Development
Register 3 for the price of 2 with the coupon code rcdvb!
Dear Colleague,

The International Diabetes Federation estimates that more than 285 million people world-wide have diabetes and 438 million people will have this disease within 20 years. Type 2 Diabetes Mellitus (T2DM) accounts for more than 90% of all diabetes and is characterized by insulin resistance combined with relatively reduced insulin secretion. The seven major markets for diabetes are expected to grow to 35 billion in 10 years driven by patient population expansion and novel therapies.

Come and join other diabetes experts at GTC’s 6th Diabetes Drug Discovery and Development Conference and hear key thought-leader`s opinions to these questions and many more. This important meeting will be held on April 29-30, 2013 in Boston, MA. The conference will bring together the leading experts on diabetes from both industry and academia to discuss novel targets for diabetes, lessons to learn from current and clinical drug development.


6th Diabetes Drug Discovery and Development sessions:
New Therapeutic Targets for Diabetes
Clinical Drug Development in Diabetes
Diabetes and the Metabolic Syndrome Drug Development (Panel)
Obesity and Drug Development
Open Innovation
Diabetic Devices & Technology (Panel)
Cure for Type 1 Diabetes: What, why, how, and when? (Panel)

The 2013 agenda is in development
 To view the 2012 agenda, click here.
To view the speaker list, click here.

The conference will run parallel with the - 3rd Diabetes Partnering and Deal-making track

Sign up for the summit pass to have access to both tracks of the summit. Or bring a team of 3 for the price of 2 by registering with the coupon code rcdvb!


Best regards,

2013 Conference Advisory Committee
GOLD SPONSORS
MEDIA PARTNERS
Attend ALL GTC Conferences for One Year for only $3,995 ($1,990 for Acad/Govt).
Click here to sign up!

What Past Delegates Said About the Event:

"Excellent conference to engage with industry and academic collaborators and to learn about advances in technology in a setting that is very conducive to discussion and networking." - John L. Brooks III, President and Chief Executive Officer, Joslin Diabetes Center

"The conference was a great opportunity to see many of the leaders and new innovators in the field and all the latest products, technologies and emerging science that will be at the core of shaping the field in the coming years." - Kurt Graves, Executive Chairman of the Board, Intarcia Therapeutics

"A great meeting concept offering useful platform for interactions between diabetes science and business needs. Quality of presentations and panel discussion could have been much better" - Ish Khanna, Chief Adviser Preclinical, Kareus Therapeutics

“This is a great conference to get the latest strategic and technical updates and meet with industry leaders for insights into drug development and partnership”. Ming Wang,, Ph.D., Metabolic Disorders, Amgen, Inc.